Literature DB >> 9481153

Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease.

D A Revicki1, M Wood, I Wiklund, J Crawley.   

Abstract

The objective of this study was to evaluate the reliability and validity of the gastrointestinal Symptom Rating Scale (GSRS) in US patients with gastroesophageal reflux disease (GERD). Five hundred and sixteen adults with predominant heartburn symptoms of GERD were recruited from gastroenterologist and family physician practices and treated with 6 weeks of 150 mg ranitidine twice daily to identify poorly responsive symptomatic GERD. The GSRS, the Medical Outcomes Study Short Form-36 (SF-36) Health Survey and the Psychological General Well-being (PGWB) scale were administered at baseline and after 6 weeks of treatment. Reported ratings of GERD-related symptoms from physician and patient diaries were measured. The GSRS contains five scales: reflux syndrome, abdominal pain, constipation syndrome, diarrhoea syndrome and indigestion syndrome. The internal consistency reliabilities for the GSRS scales ranged from 0.61 to 0.83 and the intraclass correlation coefficients ranged from 0.42 to 0.60. The GSRS scale scores were correlated with the SF-36 and PGWB scales and with the number and severity of heartburn symptoms. Patients with two or three clinician-rated GERD-related symptoms reported worse GSRS scale scores compared with patients with fewer symptoms (p < 0.0001). Statistically significant differences in the mean GSRS scale scores were observed between treatment responders and non-responders (p < 0.0001) and patients showing a response to treatment had larger mean changes in their GSRS scales than patients not showing a response to treatment (p < 0.0001). The standardized response means ranged from 0.42 to 1.43 for the GSRS scale scores. It was concluded that the GSRS is a brief, fairly comprehensive assessment of common gastrointestinal symptoms. The GSRS has good reliability and construct validity and the GSRS scales discriminate by GERD symptom severity and are responsive to treatment. The GSRS is a useful patient-rated symptom scale for evaluating the outcomes of treatment for GERD.

Entities:  

Mesh:

Year:  1998        PMID: 9481153     DOI: 10.1023/a:1008841022998

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  24 in total

1.  A new questionnaire for gastroesophageal reflux disease.

Authors:  G R Locke; N J Talley; A L Weaver; A R Zinsmeister
Journal:  Mayo Clin Proc       Date:  1994-06       Impact factor: 7.616

2.  Quality of Life--rationale and methods for developing a disease-specific instrument for inflammatory bowel disease.

Authors:  E J Irvine
Journal:  Scand J Gastroenterol Suppl       Date:  1993

3.  The intraclass correlation coefficient as a measure of reliability.

Authors:  J J Bartko
Journal:  Psychol Rep       Date:  1966-08

4.  Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease.

Authors:  E Dimenäs; G Carlsson; H Glise; B Israelsson; I Wiklund
Journal:  Scand J Gastroenterol Suppl       Date:  1996

5.  Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens?

Authors:  E Dimenäs; H Glise; B Hallerbäck; H Hernqvist; J Svedlund; I Wiklund
Journal:  Scand J Gastroenterol       Date:  1993-08       Impact factor: 2.423

6.  The rating form of IBD patient concerns: a new measure of health status.

Authors:  D A Drossman; J Leserman; Z M Li; C M Mitchell; E A Zagami; D L Patrick
Journal:  Psychosom Med       Date:  1991 Nov-Dec       Impact factor: 4.312

7.  Functional bowel disorders. A multicenter comparison of health status and development of illness severity index.

Authors:  D A Drossman; Z Li; B B Toner; N E Diamant; F H Creed; D Thompson; N W Read; C Babbs; M Barreiro; L Bank
Journal:  Dig Dis Sci       Date:  1995-05       Impact factor: 3.199

8.  Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study.

Authors:  A L Stewart; S Greenfield; R D Hays; K Wells; W H Rogers; S D Berry; E A McGlynn; J E Ware
Journal:  JAMA       Date:  1989-08-18       Impact factor: 56.272

9.  Aspects of quality of life in gastrointestinal disease: some methodological issues.

Authors:  I Wiklund
Journal:  Scand J Gastroenterol Suppl       Date:  1995

10.  Abdominal pain in an HMO.

Authors:  A M Adelman; D A Revicki; J Magaziner; R Hebel
Journal:  Fam Med       Date:  1995-05       Impact factor: 1.756

View more
  166 in total

1.  No relation between body mass and gastro-oesophageal reflux symptoms in a Swedish population based study.

Authors:  J Lagergren; R Bergström; O Nyrén
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

Review 2.  Quality of life assessment in gastro-oesophageal reflux disease.

Authors:  E J Irvine
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

3.  Best practice in symptom assessment: a review.

Authors:  E McColl
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

4.  A study on the efficacy of rebamipide for patients with proton pump inhibitor-refractory non-erosive reflux disease.

Authors:  Kyoichi Adachi; Kenji Furuta; Hiroto Miwa; Tadayuki Oshima; Masaharu Miki; Yoshinori Komazawa; Katsuhiko Iwakiri; Takahisa Furuta; Tomoyuki Koike; Tomohiko Shimatani; Yoshikazu Kinoshita
Journal:  Dig Dis Sci       Date:  2012-02-26       Impact factor: 3.199

5.  Using GI-specific patient outcome measures in renal transplant patients: validation of the GSRS and GIQLI.

Authors:  Leah Kleinman; Anne Kilburg; Gerardo Machnicki; Randall Faull; Rowan Walker; Ramesh Prasad; Patrice Ambuehl; Udo Bahner; Mary Kay Margolis
Journal:  Qual Life Res       Date:  2006-09-14       Impact factor: 4.147

6.  Randomized controlled trial of a gluten-free diet in patients with schizophrenia positive for antigliadin antibodies (AGA IgG): a pilot feasibility study

Authors:  Deanna L. Kelly; Haley K. Demyanovich; Katrina M. Rodriguez; Daniela Ciháková; Monica V. Talor; Robert P. McMahon; Charles M. Richardson; Gopal Vyas; Heather A. Adams; Sharon M. August; Alessio Fasano; Nicola G. Cascella; Stephanie M. Feldman; Fang Liu; MacKenzie A. Sayer; Megan M. Powell; Heidi J. Wehring; Robert W. Buchanan; James M. Gold; William T. Carpenter; William W. Eaton
Journal:  J Psychiatry Neurosci       Date:  2019-07-01       Impact factor: 6.186

7.  Endoscopic full-thickness plication for the treatment of GERD: Five-year long-term multicenter results.

Authors:  Douglas Pleskow; Richard Rothstein; Richard Kozarek; Gregory Haber; Christopher Gostout; Simon Lo; Robert Hawes; Anthony Lembo
Journal:  Surg Endosc       Date:  2007-11-20       Impact factor: 4.584

8.  Heartburn in patients with gastro-oesophageal reflux disease in Germany and Sweden: a study on patients' burden of disease.

Authors:  Roger Jones; Silke Horbach; Peter Sander; Tina Rydén-Bergsten
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

9.  GERD symptoms in the general population: prevalence and severity versus care-seeking patients.

Authors:  Erica Cohen; Roger Bolus; Dinesh Khanna; Ron D Hays; Lin Chang; Gil Y Melmed; Puja Khanna; Brennan Spiegel
Journal:  Dig Dis Sci       Date:  2014-05-09       Impact factor: 3.199

10.  NSAID and aspirin use by the elderly in general practice: effect on gastrointestinal symptoms and therapies.

Authors:  Alberto Pilotto; Marilisa Franceschi; Gioacchino Leandro; Francesco Di Mario
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.